시장보고서
상품코드
1451760

여성 건강 시장 보고서 : 연령층별, 용도별, 유통 채널별, 지역별(2024-2032년)

Women´s Health Market Report by Age Group Type, Application, Distribution Channel, and Region 2024-2032

발행일: | 리서치사: IMARC | 페이지 정보: 영문 142 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 여성 건강 시장 규모는 2023년에 410억 달러에 달했습니다. 향후 IMARC Group은 2024-2032년 3.78%의 성장률(CAGR)을 보이며, 2032년까지 579억 달러에 달할 것으로 예측하고 있습니다. 고령 여성 인구증가, 노화에 수반하는 특유 건강 요구, 여성 건강에 대한 사회적 규범 및 태도의 변화, 헬스케어 서비스에 대한 액세스 향상을 위한 자금조달의 증가는 시장을 추진하는 주요 요인의 일부입니다.

여성 건강은 여성의 신체적, 정신적 웰빙에 영향을 미치는 질병과 상태의 치료와 진단에 초점을 맞춘 의학의 한 분야입니다. 생식 건강, 임산부 건강, 정신건강, 비감염성 질환 등 여성에게 큰 영향을 미칠 수 있는 다양한 전문 분야와 중점 분야를 포함합니다. 이는 여성 개인의 행복에 필수적일 뿐만 아니라 경제적 생산성, 가족 안정성, 공중 보건 결과와 관련된 더 넓은 사회적 의미도 가지고 있습니다. 또한 이러한 문제는 생물학적 요인뿐만 아니라 사회적 규범, 라이프스타일 선택 및 의료 서비스 이용에 대한 성별 차이에 영향을 받는다는 점에 유의하는 것이 중요합니다. 따라서 여성 건강에 대한 종합적인 접근 방식은 이러한 다면적 측면을 이해하고 이에 대처하는 것이 필요합니다.

여성의 고령화는 여성 건강 시장의 중요한 촉진요인입니다. 여성은 나이가 들어감에 따라 폐경, 골다공증, 심장병, 일부 암과 같은 독특한 건강 문제에 직면하게 됩니다. 이처럼 전 세계에서 고령 여성 인구가 증가하고 있으며, 고령화에 따른 건강상의 특수한 요구가 서비스 및 제품에 대한 강력한 수요를 창출하고 있습니다. 이와 함께 여성 건강에 대한 사회적 규범과 사고방식의 변화도 이 산업의 중요한 원동력이 되고 있습니다. 성별에 따른 건강관리의 권리와 필요성에 대한 인식이 높아지면서 시장에 긍정적인 영향을 미치고 있습니다. 또한 전 세계 의료비 지출 증가도 여성 건강 시장의 성장에 큰 기여를 하고 있습니다. 소득 수준이 높아짐에 따라 개인과 가족은 예방 및 치료 의료에 투자하는 경향이 강해지고 있습니다. 정부도 예산의 많은 부분을 의료에 투자하고 있습니다. 이러한 자금 지원은 의료 서비스에 대한 접근성을 높이고 여성 건강케어 연구와 제품 개발의 진전을 촉진하고 있습니다.

여성 건강 시장 동향 및 촉진요인 :

의식 제고와 정부의 구상

지난 수년간 세계 각국의 정부, 비영리 단체 및 국제기구는 여성 건강 문제에 대한 인식을 높이는 데 중요한 역할을 해왔습니다. 이는 주로 캠페인, 정책 변경, 연구 및 서비스에 대한 자금 지원을 통해 이루어졌습니다. 이러한 노력은 여성 건강 문제가 전 세계에서 주목받는 환경을 조성하고 여성 건강 상품과 서비스에 대한 수요를 증가시키는 데 기여했습니다. 또한 이러한 정부의 구상은 종종 건강 검진, 진단 테스트 및 예방 조치에 대한 규정을 포함하고 있으며, 이는 업계의 성장을 더욱 촉진하고 있습니다. 예를 들어 다양한 정부 법률은 건강 보험을 통한 예방 서비스 제공을 의무화하고 있으며, 이는 이러한 서비스에 대한 수요를 증폭시키고 있습니다.

기술의 끊임없는 발전

기술의 급속한 발전은 여성 건강 산업에 큰 영향을 미치고 있습니다. 이에 따라 진단 툴와 치료법도 진화하고 개선되어 질병을 더 잘 발견하고, 더 효과적으로 치료하고, 생존율을 높일 수 있게 되었습니다. 텔레헬스, 모바일 앱, 웨어러블 기기 등 디지털 건강 기술은 현재 여성 건강 상태를 보다 효율적으로 추적하고 관리하는 데 도움을 주고 있습니다. 인공지능과 머신러닝을 포함한 첨단 기술도 다양한 관련 문제를 진단하고 치료하는 데 활용되고 있습니다. 이러한 기술 발전은 여성에게 보다 효과적이고 개인화된 건강관리 솔루션을 보장할 뿐만 아니라 새로운 기회와 수요를 창출하여 시장 성장을 가속하고 있습니다.

만성질환 증가

암(특히 유방암과 자궁경부암), 심혈관 질환, 당뇨병, 골다공증 등 여성의 만성질환 발병률이 증가함에 따라 이러한 서비스의 필요성이 증가하고 있습니다. 세계보건기구(WHO)에 따르면 비감염성 질환, 특히 암과 심혈관 질환은 전 세계 여성 사망원인의 대부분을 차지합니다. 이와 함께 여성 만성질환의 심각한 증가는 적시에 발견하고 효과적인 치료 옵션과 예방적 치료 증가를 요구하고 있으며, 이는 여성 건강 산업의 주요 동력이 되고 있습니다. 또한 생식 건강은 여전히 시장의 중요한 측면으로 남아있습니다. 산모 사망률과 영아 사망률을 낮추기 위해 가족 계획 서비스, 산전 관리 및 안전한 출산 방법에 대한 접근성에 대한 관심이 높아지면서 시장에 더 많은 영향을 미치고 있습니다.

목차

제1장 서문

제2장 조사 범위와 조사 방법

  • 조사 목적
  • 이해관계자
  • 데이터 소스
    • 1차 정보
    • 2차 정보
  • 시장 추정
    • 보텀업 어프로치
    • 톱다운 어프로치
  • 조사 방법

제3장 주요 요약

제4장 서론

  • 개요
  • 주요 산업 동향

제5장 세계의 여성 건강 시장

  • 시장 개요
  • 시장 실적
  • COVID-19의 영향
  • 시장 예측

제6장 시장 내역 : 연령층별

  • 50세 이상
    • 시장 동향
    • 주요 부문
      • 폐경후 골다공증
      • 자궁내막증 및 자궁근종
      • 갱년기 장애
    • 시장 예측
  • 기타
    • 시장 동향
    • 시장 예측

제7장 시장 내역 : 용도별

  • 피임약
    • 시장 동향
    • 시장 예측
  • 골다공증
    • 시장 동향
    • 시장 예측
  • 갱년기 장애
    • 시장 동향
    • 시장 예측
  • 불임
    • 시장 동향
    • 시장 예측
  • 기타
    • 시장 동향
    • 시장 예측

제8장 시장 내역 : 유통 채널별

  • 병원 약국
    • 시장 동향
    • 시장 예측
  • 소매 약국
    • 시장 동향
    • 시장 예측
  • 온라인 약국
    • 시장 동향
    • 시장 예측

제9장 시장 내역 : 지역별

  • 북미
    • 미국
      • 시장 동향
      • 시장 예측
    • 캐나다
      • 시장 동향
      • 시장 예측
  • 아시아태평양
    • 중국
      • 시장 동향
      • 시장 예측
    • 일본
      • 시장 동향
      • 시장 예측
    • 인도
      • 시장 동향
      • 시장 예측
    • 한국
      • 시장 동향
      • 시장 예측
    • 호주
      • 시장 동향
      • 시장 예측
    • 인도네시아
      • 시장 동향
      • 시장 예측
    • 기타
      • 시장 동향
      • 시장 예측
  • 유럽
    • 독일
      • 시장 동향
      • 시장 예측
    • 프랑스
      • 시장 동향
      • 시장 예측
    • 영국
      • 시장 동향
      • 시장 예측
    • 이탈리아
      • 시장 동향
      • 시장 예측
    • 스페인
      • 시장 동향
      • 시장 예측
    • 러시아
      • 시장 동향
      • 시장 예측
    • 기타
      • 시장 동향
      • 시장 예측
  • 라틴아메리카
    • 브라질
      • 시장 동향
      • 시장 예측
    • 멕시코
      • 시장 동향
      • 시장 예측
    • 기타
      • 시장 동향
      • 시장 예측
  • 중동 및 아프리카
    • 시장 동향
    • 시장 내역 : 국가별
    • 시장 예측

제10장 촉진요인, 억제요인, 기회

  • 시장 개요
  • 촉진요인
  • 억제요인
  • 기회

제11장 밸류체인 분석

제12장 Porter's Five Forces 분석

  • 개요
  • 구매자의 교섭력
  • 공급 기업의 교섭력
  • 경쟁의 정도
  • 신규 진출업체의 위협
  • 대체품의 위협

제13장 가격 분석

제14장 경쟁 구도

  • 시장 구조
  • 주요 기업
  • 주요 기업의 개요
    • Abbott Laboratories
    • AbbVie Inc.
    • Agile Therapeutics Inc.
    • Amgen Inc.
    • Bayer AG
    • F. Hoffmann-La Roche AG
    • Ferring Pharmaceuticals
    • FUJIFILM Holdings Corporation
    • Hologic Inc.
    • Lupin Limited
    • Novo Nordisk A/S
    • Pfizer Inc.
KSA 24.04.17

The global women's health market size reached US$ 41.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 57.9 Billion by 2032, exhibiting a growth rate (CAGR) of 3.78% during 2024-2032. The growing population of elderly women, and the specific health needs associated with aging, changing societal norms and attitudes towards women's health, and the rising funding for better access to healthcare services are some of the major factors propelling the market.

Women's health refers to the branch of medicine that focuses on the treatment and diagnosis of diseases and conditions that affect a woman's physical and emotional well-being. It encompasses a broad range of specialties and focus areas, such as reproductive health, maternal health, mental health, and non-communicable diseases, which can all significantly impact women. It is vital not only for the individual well-being of women, but it also has wider societal implications relating to economic productivity, family stability, and public health outcomes. Furthermore, it's important to note that these issues are influenced by biological factors as well as gender-related differences in societal norms, lifestyle choices, and access to healthcare. Thus, a comprehensive approach to women's health necessitates understanding and addressing these multifaceted dimensions.

The aging female population is a key driver of the women's health market. As women age, they face a specific set of health challenges including menopause, osteoporosis, heart disease, and certain types of cancer. This increasing population of elderly women globally, and the specific health needs associated with aging, create a robust demand for services and products. Along with this, changing societal norms and attitudes towards women's health have also acted as a significant driver in this industry. Therefore, the growing recognition of rights and the need for gender-specific healthcare is positively influencing the market. In addition, the rise in healthcare spending across the globe also contributes significantly to the growth of the women's health market. With higher income levels, individuals and families are more inclined to invest in preventive and curative healthcare. Governments, too, are dedicating larger portions of their budgets towards healthcare. This accelerated funding allows for better access to healthcare services and promotes advancements in women's healthcare research and product development.

Women's Health Market Trends/Drivers:

Increased Awareness and Government Initiatives

Over the past few years, governments across the globe, non-profit organizations, and international agencies have played an instrumental role in heightening awareness about women's health issues. This has been primarily achieved through campaigns, policy changes, and funding for research and services. These initiatives have fostered an environment where health matters are gaining global attention, leading to increased demand for women's health products and services. Moreover, these government initiatives often include provisions for health screenings, diagnostic tests, and preventive measures, which further drive the growth of the industry. Various government acts, for instance, make preventative services for a mandatory health insurance provision, amplifying the demand for such services.

Continuous Advancements in Technology

The rapid advancement in technology has significantly impacted the women's health industry. Along with this, diagnostic tools and therapies have evolved and improved, which have led to better disease detection, more effective treatments, and increased survival rates. Digital health technologies, such as telehealth, mobile apps, and wearable devices are now assisting women in tracking and managing their health more efficiently. Advanced technologies, including artificial intelligence and machine learning, are also being employed in the diagnosis and treatment of various related issues. These technological advancements ensure more effective and personalized healthcare solutions for women but also stimulate the market's growth by creating new opportunities and demands.

Rising Incidences of Chronic Diseases

An increasing incidence of chronic diseases among women, such as cancer (specifically breast and cervical cancer), cardiovascular diseases, diabetes, and osteoporosis, is driving the need for these services. According to global health organizations, non-communicable diseases, notably cancer, and cardiovascular diseases, are responsible for the majority of deaths among women across the globe. In confluence with this, this alarming rise in chronic conditions among women necessitates timely detection, effective treatment options, and increased preventive care, which are the major propellers for the women's health industry. Also, reproductive health remains a significant aspect of the market. The industry is witnessing a growing emphasis on access to family planning services, prenatal care, and safe childbirth practices to reduce maternal and infant mortality rates, further impacting the market.

Women's Health Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global women's health market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on age group type, application and distribution channel.

Breakup by Age Group Type:

50 Years and Above

Postmenopausal Osteoporosis

Endometriosis and Uterine Fibroids

Menopause

Others

50 Years and Above dominate the market

The report has provided a detailed breakup and analysis of the market based on the age group type. This includes 50 years and above (postmenopausal osteoporosis, endometriosis and uterine fibroids, and menopause), and others. According to the report, 50 years and above represented the largest segment.

The 50 years and above age group in the industry has witnessed significant market drivers over the past decades. One of the primary factors contributing to this trend is the global demographic shift towards an aging population, leading to an increased number of women entering this age bracket. Additionally, advancements in healthcare technology and increased access to medical services have enabled better diagnoses and treatments for age-related health conditions in women. In addition, the growing awareness among this demographic regarding preventive healthcare measures and wellness has influenced the demand for specialized products and services catering to their unique needs. As women in this age group seek to maintain their health and quality of life, there is an escalating demand for menopause-related treatments, bone health supplements, and preventive screenings. This market segment's potential for growth is further bolstered by the expanding focus on research, allowing the industry to offer targeted and evidence-based solutions.

Breakup by Application:

Contraceptives

Osteoporosis

Menopause

Infertility

Others

Contraceptives dominate the market

A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes contraceptives, osteoporosis, menopause, infertility, and others. According to the report, contraceptives represented the largest segment.

The industry has been significantly influenced by the increasing global awareness of family planning and reproductive health. Governments, organizations, and healthcare providers are emphasizing the importance of safe and effective contraceptive methods to empower women to make informed choices about their reproductive health. Additionally, advancements in medical technology have led to the development of a wide range of contraceptive options, offering women more choices and personalized solutions to suit their preferences and needs. In confluence with this, the shifting societal attitudes towards women's rights and gender equality have resulted in greater access to contraceptive products and services, enabling women to take control of their reproductive decisions. Furthermore, the growing prevalence of sexually transmitted infections has reinforced the importance of using contraceptives as a means of protection.

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Hospital pharmacies dominate the market

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies represented the largest segment.

The hospital pharmacies distribution channel in the industry is experiencing significant market drivers that shape its growth and development. One of the key factors contributing to the prominence of this distribution channel is the rising demand for specialized women's health medications and treatments within hospital settings. Hospitals serve as essential centers for comprehensive medical care, making them an ideal platform to provide a wide range of women's health products, including contraceptives, hormone therapies, fertility medications, and prenatal supplements. Additionally, the increasing prevalence of chronic conditions, such as gynecological disorders and menopause-related symptoms, has led to a growing need for prompt access to medications and treatments, which hospital pharmacies can efficiently cater to. Furthermore, regulatory initiatives and healthcare policies that encourage hospitals to maintain well-stocked pharmacies with a focus on women's health contribute to the expansion of this distribution channel.

Breakup by Region:

North America

United States

Canada

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The industry in North America is influenced by the region's aging population. It contributes to an increased demand for women's health services and products catering to menopausal and post-menopausal women. Additionally, the growing awareness and emphasis on preventive healthcare measures among women drive the market for screenings, wellness programs, and specialized treatments. In addition, advancements in medical research and technology facilitate the development of innovative solutions, encouraging investment and competition in the industry.

Moreover, favorable healthcare policies and insurance coverage for women's health services bolster market growth. Apart from this, shifting cultural attitudes towards women's empowerment and gender equality enhances access to comprehensive healthcare, including family planning and contraceptive options. Furthermore, strategic marketing efforts and educational campaigns by industry players to promote health and wellness further fuel market expansion.

Competitive Landscape:

The global women's health market is experiencing significant growth due to the growing investments in research and development to create new and improved women's health products, including contraceptives, fertility treatments, hormone therapies, prenatal vitamins, and other related medications. Along with this, companies are promoting their women's health products and services through marketing campaigns to grow awareness among healthcare providers and consumers. These campaigns often focus on promoting the benefits and efficacy of their offerings. Numerous companies are forming partnerships with healthcare providers, clinics, hospitals, and other organizations to expand their market reach and enhance distribution channels, impacting the market. Moreover, the introduction of educational programs for healthcare professionals to ensure proper understanding and usage of their products is contributing to the market.

The report has provided a comprehensive analysis of the competitive landscape in the global women's health market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abbott Laboratories

AbbVie Inc.

Agile Therapeutics Inc.

Amgen Inc.

Bayer AG

Hoffmann-La Roche AG

Ferring Pharmaceuticals

FUJIFILM Holdings Corporation

Hologic Inc.

Lupin Limited

Novo Nordisk A/S

Pfizer Inc.

Recent Developments:

In June 2023, AbbVie Inc. revealed the names of the 20 amazing women business owners who will receive grants and mentoring from the IFundWomen and BOTOX(R) Cosmetic award programme.

In October 2021, Abbott Laboratories stated that it has signed a three-year contract to serve as the Real Madrid Football Club's Global Health Sciences and Nutrition Partner and Global Partner of the Real Madrid Foundation, whose mission is to spread the ideals of sport to adolescents all over the world. In addition to providing nutritional assistance for the inaugural men's and women's Academy teams as well as new product development, the alliance will also benefit at-risk youngsters in 80 countries via educational, sporting, and social welfare initiatives.

In June 2023, Agile Therapeutics Inc. stated that MMCAP Infuse Members would have access to the Twirla (levonorgestrel and ethinyl estradiol) transdermal system. The business anticipates that this improved supply will have a favorable effect on demand growth and factory sales in the non-retail channel, which climbed 20% and 15%, respectively, from the fourth quarter of 2022 to the first quarter of 2023.

Key Questions Answered in This Report:

  • How has the global women's health market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global women's health market?
  • What is the impact of each driver, restraint, and opportunity on the global women's health market?
  • What are the key regional markets?
  • Which countries represent the most attractive women's health market?
  • What is the breakup of the market based on the age group?
  • Which is the most attractive age group in the women's health market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the women's health market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the women's health market?
  • What is the competitive structure of the global women's health market?
  • Who are the key players/companies in the global women's health market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Women's Health Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Age Group

  • 6.1 50 Years and Above
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Postmenopausal Osteoporosis
      • 6.1.2.2 Endometriosis and Uterine Fibroids
      • 6.1.2.3 Menopause
    • 6.1.3 Market Forecast
  • 6.2 Others
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Contraceptives
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Osteoporosis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Menopause
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Infertility
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AbbVie Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Agile Therapeutics Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 Amgen Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Bayer AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 F. Hoffmann-La Roche AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Ferring Pharmaceuticals
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 FUJIFILM Holdings Corporation
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Hologic Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Lupin Limited
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Novo Nordisk A/S
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Pfizer Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제